Research Topics
| L RuizSummaryAffiliation: Hospital Universitari Germans Trias i Pujol Country: Spain Publications
| Collaborators
|
Detail Information
Publications
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infectionL Ruiz
Retrovirology Laboratory, IrsiCaixa Foundation and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
AIDS 15:F19-27. 2001..To evaluate whether controlled re-exposures to autologous HIV-1 could boost HIV-specific immunity and limit virus replication in patients with chronic HIV-1 infection...- Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus loadA Arno
Retrovirology Laboratory irsiCaixa Foundation, Immunology Department, HIV Unit, University Hospital Germans Trias i Pujol, Barcelona, Spain
J Infect Dis 180:56-60. 1999..05). Subcutaneous rIL-2 once a day in combination with HAART was well tolerated and improved immunologic surface markers in patients with advanced HIV infection... - Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene StudyLidia Ruiz
Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
J Infect Dis 188:977-85. 2003..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen... - Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled studyL Ruiz
IrsiCaixa Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
J Acquir Immune Defic Syndr 27:229-36. 2001..Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy... - Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-upE Negredo
Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Antivir Ther 4:23-8. 1999..Maintenance of viral suppression was equivalent in both treatment groups. Additional data with longer follow-up are needed to confirm these results... - High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic responseR Paredes
Retrovirology Laboratory Institut de Recerca de la SIDA Caixa, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain
J Acquir Immune Defic Syndr 22:132-8. 1999..This therapeutic efficacy is strongly implemented by a switch at the lower HIV-1 RNA levels... - Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapyA Tuldrá
HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Spain
J Acquir Immune Defic Syndr 25:221-8. 2000..Interventions to ensure a high level of adherence during a relatively long-term period of therapy are necessary... - Short-term anti-HIV activity of the combination of didanosine and hydroxyureaB Clotet
Internal Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Antivir Ther 1:189-93. 1996..In conclusion, hydroxyurea in combination with didanosine was well tolerated and led to a reduction in viral load mainly in patients who were initially naive to didanosine... - Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremiaM A Martinez
Laboratori de Retrovirologia, Hospital Universitari Germans Trias i Pujol, Badalona, 08916, Spain
Virology 256:180-7. 1999..Finally, the genetic analysis of the env gene shows a reduction in PBMC env viral population diversity after long-term response to the therapy in all the patients analyzed... 
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenzJ M Llibre
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
J Antimicrob Chemother 62:909-13. 2008..To evaluate the expected activity of etravirine in clinical samples, according to mutational patterns associated with decreased virological response (VR)...
Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA and CD45RO phenotype from tonsils, cord and adult peripheral bloodM Bofill
Institucio Catalana de Recerca i Estudis Avancats, Badalona, Spain
Clin Exp Immunol 138:460-5. 2004....- Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10G Coma
, Badalona, Spain
Clin Exp Immunol 145:535-44. 2006..In particular, those that may regulate angiogenesis and promote the recruitment of monocytes, activated T cells (CXCL9 and CXCL10) and granulocytes (CXCL8)... - Longitudinal study on mitochondrial effects of didanosine-tenofovir combinationSonia Lopez
Mitochondrial Research Laboratory, Muscle Research Unit, Internal Medicine Department, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
AIDS Res Hum Retroviruses 22:33-9. 2006..The particular relevance of either ddI, TDF, or any interaction between them in such a mitochondrial dysfunction remains to be established... - Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimenCecilia Cabrera
IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
AIDS 20:2075-80. 2006..To analyse the genetic changes in the gp41 protein in HIV-infected patients with detectable plasma viraemia receiving a long-term salvage enfuvirtide regimen... - Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevanceMargarita Bofill
Institució Catalana de Recerca i Estudis Avangats, HIV Unit, Hospital Universitari Germans Trias i Pujol, Ctra Canyet s n 08916 Badalona, Barcelona, Spain
AIDS Res Hum Retroviruses 22:893-6. 2006..However, the probability of restarting therapy in these two groups of patients was independent of the levels of naive T cells, RTEs, or TRECs... - Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtideAnna Bonjoch
Lluita contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, , Badalona, Spain
AIDS 20:1896-8. 2006..5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available... - The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapyEugenia Negredo
Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
AIDS 20:619-21. 2006..Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4... - Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patientsMonica Guma
Molecular Immunopathology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
J Infect Dis 194:38-41. 2006..These results support the conclusion that changes in the NKR repertoire in HIV1-positive patients are related to a concomitant HCMV infection... - The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypesDavid A van de Vijver
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, G04-614, 3584 CX Utrecht, The Netherlands
J Acquir Immune Defic Syndr 41:352-60. 2006..Because of differences in minor protease substitutions, protease inhibitor resistance could be enhanced in particular subtypes once the relevant major substitutions are selected... - Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusRika Draenert
Howard Hughes Medical Institute, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
J Exp Med 203:529-39. 2006..These results reveal considerable concordance of adaptive cellular and humoral immune responses and HIV evolution in the same genetic environment, suggesting constraints on mutational pathways to HIV immune escape... - Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patientsJose Molto
Lluita contra la SIDA Foundation, HIV Unit, Germans Trias i Pujol Hospital, Badalona, Spain
Antivir Ther 11:47-51. 2006..To assess if enfuvirtide (ENF) increases antiviral activity of a highly active four-drug antiretroviral (ARV) regimen containing lopinavir/ritonavir, efavirenz, lamivudine and tenofovir in ARV-naive, HIV-infected patients... - Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patientsLidia Ruiz
Fundació IrsiCaixa and HIV Clinical Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
AIDS 21:169-78. 2007..We evaluated the safety of CD4 cell count and plasma HIV-1 RNA (pVL)-guided treatment interruptions (GTI) and determined predictors of duration of treatment interruption... - Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1-infected patientsGuillermo Robert de Arquer
Fundacio irsiCaixa, HIVACAT, Hospital Universitari Germans Trias i Pujol, Ctra Canyet sn, 08916 Badalona, Spain
J Leukoc Biol 82:72-8. 2007..Furthermore, the percentage of IL-12Rbeta1-positive cells correlated inversely with the CD4 nadir of patients, suggesting that deregulation of the IL-12 and IL-18 pathways may play a role in the immunopathogenesis of HIV-1 infection... - HIV-1 subtypes and response to combination antiretroviral therapy in EuropeWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
Antivir Ther 11:707-15. 2006..Antiretroviral drugs have predominantly been developed in Western Europe/North America on the basis of the most prevalent subtype, B. However, non-B subtypes are increasingly spreading worldwide... - Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA StudyWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom
J Acquir Immune Defic Syndr 48:324-33. 2008..To investigate prevalence of transmitted drug-resistant human immunodeficiency virus (TDR) and factors associated with TDR and to compare virological and CD4 count response to combination antiretroviral therapy... - Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptionsLaila Darwich
IrsiCaixa Foundation, Center for Epidemiological Studies on Sexually Transmitted Infections and AIDS in Catalonia, Barcelona, Spain
AIDS Res Hum Retroviruses 24:725-32. 2008..A genotypic profile could provide clinicians with a predictive tool for time off therapy when TI is required in patients with suppressed viremia in whom nadir CD4(+) count is not available... - Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDAWendy P Bannister
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 22:367-76. 2008..To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens... - Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAARTEugenia Negredo
Lluita contra la SIDA Foundation, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916 Badalona, Barcelona, Spain
J Antimicrob Chemother 61:400-4. 2008..Cellular cholesterol is essential for HIV replication and may control HIV spread. HIV, in turn, appears to control cholesterol metabolism... - Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosineAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Roma, 00168, Italy
J Infect Dis 196:1645-53. 2007..Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed... - Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patientsFrancesca Ceccherini-Silberstein
Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
J Infect Dis 196:1180-90. 2007..A negative association between the polymorphism F214L and type 1 thymidine analogue (TA) mutations (TAMs) has been observed. However, the virological response to TAs according to the detection of F214L has not been evaluated... - Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatmentsCésar Garriga
Centro de Biologia Molecular Severo Ochoa, CSIC Universidad Autonoma de Madrid, Cantoblanco, Madrid, Spain
J Med Virol 79:1617-28. 2007.... - Coinfection and superinfection in patients with long-term, nonprogressive HIV-1 diseaseConcepcion Casado
Centro Nacional de Microbiologia Instituto de Salud Carlos III, Madrid, Spain
J Infect Dis 196:895-9. 2007..Dual infections occur in patients with long-term, nonprogressive disease, with no immediate clinical manifestations. Such occurrences could indicate a general phenomenon in natural HIV-1 infections... - The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder
The HIV Resistance Response Database Initiative, London, UK
Antivir Ther 12:15-24. 2007..The choice of an alternative regimen may be guided by a drug-resistance test. However, interpretation of resistance from genotypic data poses a major challenge... - Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimenAlessandro Cozzi-Lepri
Royal Free and University College Medical School, London, UK
AIDS 21:721-32. 2007..To estimate the extent of drug resistance accumulation in patients kept on a virologically failing regimen and its determinants in the clinical setting... - Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapyAlessandro Cozzi-Lepri
Royal Free and University College Medical School, London, UK
Antivir Ther 10:791-802. 2005.... - Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical managementAnnemarie M J Wensing
Eijkman Winkler Institute, Department of Virology, University Medical Center Utrecht, The Netherlands
J Infect Dis 192:958-66. 2005..These data argue for testing all drug-naive patients and are of relevance when guidelines for management of postexposure prophylaxis and first-line therapy are updated... - HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failureJulia G Prado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
Clin Infect Dis 41:729-37. 2005..03) and corroborated the p24 kinetics data. CONCLUSIONS: This study shows that accumulation of MDR mutations during long-term antiretroviral treatment results, albeit not in all cases, in reductions of viral fitness... - Virological rebound after suppression on highly active antiretroviral therapyAmanda Mocroft
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, UK
AIDS 17:1741-51. 2003..Treatment-naive patients were at a lower risk of rebound, but among drug-experienced patients, those who added new nucleosides had a lower risk of rebound, as were patients with a good immunological response... - A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapyJan Weber
Department of Virology, Lerner Research Institute, Cleveland Clinic Foundation, NN10, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Gen Virol 84:2217-28. 2003..However, this new assay, based on HIV-1 isolates, may be useful to quantify replicative fitness in viruses from patients treated simultaneously with antiretroviral drugs targeting different genomic regions of HIV-1 (e.g. pol and env)... - Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trialJavier Martinez-Picado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Carretera de Canyet s n, 08916 Badalona, Spain
Ann Intern Med 139:81-9. 2003..Mathematical modeling has suggested that alternating antiretroviral regimens while patients' viral load remains suppressed would minimize HIV resistance mutations... - Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individualsJavier Martinez-Picado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
J Virol 76:12344-8. 2002..Analyses of length variation and of clonal sequences demonstrated highly unpredictable evolution, which may limit the strengthening of HIV-specific immune responses by STIs because of the variability in exposure to viral antigens... - Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohortsBonaventura Clotet
Retrovirology Laboratory irsiCaixa Foundation, Barcelona, Spain
HIV Clin Trials 3:316-23. 2002..L90M occurs in only 5% of cases. These results are of significance for determining the feasibility of initiating a second PI after first-line nelfinavir failure... - Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapineEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, , Badalona, Spain
AIDS 16:1383-9. 2002..These changes are expected to reduce the risk of cardiovascular disease in HIV-1-infected patients on highly active antiretroviral therapy... - Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacityJulia G Prado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, , Ctra. de Canyet s/n, 08916 Badalona, Spain
AIDS 16:1009-17. 2002..This study also provides data on the concordance of replication capacity measurements generated using rapid single-cycle growth and competition assays... - Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptionsJavier Martinez-Picado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
AIDS 16:895-9. 2002..The potential for selection of drug-resistant quasi-species remains a major concern of such a treatment strategy... - Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyJacques Fellay
Division of Infectious Diseases, University Hospital of Lausanne, Lausanne, Switzerland
Lancet 359:30-6. 2002..This variability could have a genetic basis. We did a pharmacogenetics study to analyse the association between response to antiretroviral treatment and allelic variants of several genes... - Clinical utility of HIV-1 genotyping and expert advice: the Havana trialCristina Tural
HIV Clinical Unit and IrsiCaixa Retrovirology Laboratory, Hospital Universitari Germans Trias i Pujol, , Badalona, Spain
AIDS 16:209-18. 2002..The expert advice also showed virologic benefit in the second failure group... - Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppressionEugenia Negredo
Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Clin Infect Dis 34:504-10. 2002..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective... - Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infectionSimon D W Frost
Department of Pathology, University of California, San Diego, California 92103, USA
J Virol 76:968-79. 2002.... - Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infectionRika Draenert
Howard Hughes Medical Institute, Charlestown, MA 02129, USA
J Exp Med 199:905-15. 2004..These results demonstrate that allele-associated sequence variation within the flanking region of CTL epitopes can alter antigen processing. Identifying such mutations is of major relevance in the construction of vaccine sequences... - Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1Javier Martinez-Picado
IrsiCaixa Foundation Hospital Germans Trias i Pujol, Ctra de Canyet, s n 08916 Badalona, Spain
J Virol 79:5907-13. 2005..The potential clinical relevance of protease inhibitor hypersusceptibility and low replication capacity to virologic response to protease inhibitor-based therapies deserves to be investigated further... - Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch StudyEugenia Negredo
Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Antivir Ther 9:889-93. 2004..Alternation of antiretroviral drug regimens has been proposed as a novel treatment strategy for HIV infection. However, some concerns persist regarding antiviral efficacy, adherence, toxicity and resistance evolution in the long term... - Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjectsJose Molto
HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
AIDS Res Hum Retroviruses 20:1283-8. 2004..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision... - Evidence for preferential genotyping of a minority human immunodeficiency virus population due to primer-template mismatching during PCR-based amplificationJavier Martinez-Picado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
J Clin Microbiol 43:436-8. 2005..This observation might help to explain some unexpected HIV-1 genotypes... - Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study)Eugenia Negredo
Department of Internal Medicine, Lluita contra la SIDA and IrsiCaixa Foundations, Germans Trias i Pujol Hospital, Badalona, Universitat Autonoma de Barcelona, Barcelona, Spain
J Acquir Immune Defic Syndr 38:47-52. 2005..To compare the efficacy and safety of a nucleoside-sparing approach with a conventional highly active antiretroviral therapy (HAART) regimen in antiretroviral-experienced patients with prolonged viral suppression... - Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA studyCecilia Cabrera
IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Badalona, Spain
Antivir Ther 9:787-800. 2004..Therefore, the interpretation of genotypic resistance for predicting response to regimens containing abacavir remains a major challenge... - Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adultsEsteban Ribera
Servicio de Enfermedades Infecciosas, Hospital Universitari Vall d Hebron, Paseo Vall Hebron 119 129, 08035 Barcelona, Spain
Antimicrob Agents Chemother 48:4256-62. 2004.... - Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215Julia G Prado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, , Badalona, Spain
Virology 326:103-12. 2004..Therefore, the RT residue 215 plays a critical role in both replication capacity and drug resistance of multidrug-resistant viruses containing the i69SS... - Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approachEugenia Negredo
Lluita contra la SIDA Foundation, Germans Trias i Pujol Hospital, Badalona, Spain
Antivir Ther 9:335-42. 2004..To assess the efficacy and safety of a once-daily antiretroviral regimen in HAART-experienced subjects with long-lasting viral suppression... - Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral loadEugenia Negredo
Lluita contra la SIDA and Irsicaixa Foundations Germans Trias i Pujol Hospital, Badalona, Spain
AIDS 18:459-63. 2004..We recently observed a significant CD4 cell count decline in patients receiving didanosine (ddI) 400 mg, tenofovir (TDF) and nevirapine (NVP), despite virological suppression... - Lack of longitudinal intrapatient correlation between p24 antigenemia and levels of human immunodeficiency virus (HIV) type 1 RNA in patients with chronic hiv infection during structured treatment interruptionsJulia G Prado
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
J Clin Microbiol 42:1620-5. 2004.... - Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmissionNuria Izquierdo Useros
IrsiCaixa Foundation, Badalona, Spain
J Virol 81:7559-70. 2007.... - Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding regionCristina Villena
IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Ctra de Canyet s n, 08916 Badalona, Spain
J Virol 81:4713-21. 2007..These effects correlated with impaired Gag cleavage and could be attributed to delayed maturation and decreased production of active protease in those variants...